What's new? Log in Free sign up

AC Immune (ACIU)

Company Profile

Company profile

Ticker

ACIU

Exchange

Website

www.acimmune.com

CEO

Dr. Andrea Pfeifer Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

ERA GROUP INC.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

ACIU stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Current report (foreign)

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

Current report (foreign)

Current report (foreign)

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b Re𝜏ain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease

AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions

Prospectus supplement for primary offering

Current report (foreign)

Current report (foreign)

Latest ownership filings

View all

AFFIRIS AG in Liqu

BIOTECHNOLOGY VALUE FUND L P

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

AFFIRIS AG in Liqu

Notice of proposed sale of securities

BIOTECHNOLOGY VALUE FUND L P

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart ACIU financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from AC Immune earnings reports.

Institutional ownership, Q4 2024

ACIU institutional ownership history Ownership history

73.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	50	48	+4.2%
Opened positions	11	6	+83.3%
Closed positions	9	8	+12.5%
Increased positions	12	9	+33.3%
Reduced positions	13	19	-31.6%

13F shares	Current	Prev Q	Change
Total value	73.03 bn	105.87 bn	-31.0%
Total shares	73.40 mm	74.23 mm	-1.1%
Total puts	0.00	12.40 k	EXIT
Total calls	31.30 k	150.20 k	-79.2%
Total put/call ratio	–	0.1	–

Largest owners	Shares	Value	Change
Biotechnology Value Fund L P	19.52 mm	$57.98 mm	0.0%
BVF	19.52 mm	$52.71 bn	0.0%
dievini Hopp BioTech holding GmbH & Co KG	16.32 mm	$0.00	0.0%
AFFiRiS	6.58 mm	$30.06 mm	0.0%
LLY Eli Lilly and	3.62 mm	$0.00	0.0%
BlackRock	2.21 mm	$5.97 bn	-17.3%
Redmile	1.03 mm	$2.79 bn	-38.9%
WFC Wells Fargo & Company	995.64 k	$2.69 bn	-10.1%
Platinum Investment Management	952.07 k	$2.57 bn	0.0%
Renaissance Technologies	740.20 k	$2.00 bn	+14.6%

Largest transactions	Shares	Bought/sold	Change
Redmile	1.03 mm	-659.87 k	-38.9%
BlackRock	2.21 mm	-461.79 k	-17.3%
NTRS Northern Trust	403.03 k	+403.03 k	NEW
Assenagon Asset Management	0.00	-223.88 k	EXIT
Acadian Asset Management	198.38 k	+152.37 k	+331.2%
WFC Wells Fargo & Company	995.64 k	-112.40 k	-10.1%
MS Morgan Stanley	166.56 k	+101.61 k	+156.5%
Eversept Partners	0.00	-99.31 k	EXIT
Renaissance Technologies	740.20 k	+94.19 k	+14.6%
Alps Advisors	0.00	-76.63 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

AC Immune ACI-24.060 Was Generally Safe And Well Tolerated In Individuals With Down Syndrome With No Serious Adverse Events Related To The Study Drug

No cases of amyloid-related imaging abnormalities observed in this study population. Based upon these findings, AC Immune plans to open the high-dose cohort in ABATE in individuals with Down syndrome.

Press releases

From Benzinga Pro

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.